Eloxx Pharmaceuticals, Inc. (ELOX): Form 8-K filed 2026-10-22
- Accepted by EDGAR
- 2026-10-21 19:31 ET
- Event date
- 2026-10-19
- Accession no.
- 0001193125-26-428116
- Original filing
- SEC EDGAR filing index
Items reported
- Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
A director or a named officer (such as the CEO or CFO) left or was appointed, or certain executive compensation arrangements were adopted or changed. - Item 8.01: Other Events
A voluntary disclosure of an event the company considers important to security holders that no other Item covers, such as a dividend declaration, a buyback program, litigation updates or product news.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | 8-K | d462611d8k.htm |
This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.